Stable pharmaceutical composition of tnfr:fc fusion protein

Abstract

The present invention relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc). More particularly, it relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc), phosphate-citrate buffer. It also relates to the methods of manufacturing the composition, method of administration and kits containing the same.

1 .- 20 . (canceled) 
     
     
         21 . A stable liquid pharmaceutical composition comprising Etanercept phosphate-citrate buffer, glycine, sucrose, and sodium chloride. 
     
     
         22 . The pharmaceutical composition of  claim 21  comprising 10 mg/ml to 100 mg/ml of Etanercept, about 10 mM to 100 mM of phosphate-citrate buffer, about 10 mM to 300 mM glycine, about 50 mM to 120 mM sodium chloride and about 0.5 wt % to 10 wt % sucrose. 
     
     
         23 . The stable pharmaceutical composition of  claim 21  wherein the composition has a pH in the range of 5 to 7. 
     
     
         24 . The stable pharmaceutical composition of  claim 21  wherein the composition is sterile and ready for parenteral administration. 
     
     
         25 . The pharmaceutical composition of  claim 21  comprising 10 mg/ml to 100 mg/ml of Etanercept, about 10 mM to 100 mM of phosphate-citrate buffer, about 10 mM to 300 mM glycine, about 0 mM to 150 mM sodium chloride and about 0.5 wt % to 10 wt % sucrose. 
     
     
         26 . The pharmaceutical composition of  claim 22  comprising 50 mg/ml of Etanercept about 16.6 mM of phosphate buffer, about 15.3 mM of citrate buffer, about 75 mM glycine, about 65 mM sodium chloride and about 1 wt % sucrose. 
     
     
         27 . The pharmaceutical composition of  claim 22  comprising 50 mg/ml of Etanercept about 31.9 mM of phosphate-citrate buffer, about 75 mM glycine, about 65 mM sodium chloride and about 1 wt % sucrose.